Microbiology of sputum from patients at cystic fibrosis centers in the United States
- PMID: 9675470
- DOI: 10.1086/514631
Microbiology of sputum from patients at cystic fibrosis centers in the United States
Abstract
During a phase III national collaborative study of aerosolized tobramycin (1 July 1995 through 30 September 1996), the microbiology of specimens from 595 patients at 69 cystic fibrosis (CF) centers was examined. Samples from three screening visits were processed in a single laboratory by means of standardized techniques for identification and susceptibility testing. From 1,753 pretreatment specimens, 5,128 pathogens were isolated (average, 2.9/specimen). Of the 3,936 Pseudomonas aeruginosa isolates, 56.7% were mucoid. The specimens of 125 patients (21.0%) yielded tobramycin-resistant P. aeruginosa (213 isolates); 61 (10.3%), Stenotrophomonas maltophilia; and 52 (8.7%), Alcaligenes xylosoxidans. Isolation of Burkholderia cepacia was an exclusion criterion. Only visit 3 sputum samples were cultured for gram-positive organisms and fungi (n = 465 patients); samples from 201 patients (43.2%) yielded Staphylococcus aureus (18.8% of isolates were oxacillin-resistant), and those from 114 (24.5%) yielded an Aspergillus species. Compared with the Cystic Fibrosis Foundation Patient Registry, the current study identified many more patients colonized with S. maltophilia, A. xylosoxidans, Aspergillus species, and oxacillin-resistant S. aureus, suggesting the utility of standardized processing of CF specimens.
Similar articles
-
Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.J Infect Dis. 1999 May;179(5):1190-6. doi: 10.1086/314727. J Infect Dis. 1999. PMID: 10191222 Clinical Trial.
-
Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008.Pediatr Pulmonol. 2010 Apr;45(4):363-70. doi: 10.1002/ppul.21198. Pediatr Pulmonol. 2010. PMID: 20232473
-
Comparison of two culture methods for detection of tobramycin-resistant gram-negative organisms in the sputum of patients with cystic fibrosis.J Clin Microbiol. 2002 Jan;40(1):26-30. doi: 10.1128/JCM.40.1.26-30.2002. J Clin Microbiol. 2002. PMID: 11773088 Free PMC article.
-
Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis.Drugs. 2003;63(22):2501-20. doi: 10.2165/00003495-200363220-00015. Drugs. 2003. PMID: 14609360 Review.
-
Emerging bacterial pathogens and changing concepts of bacterial pathogenesis in cystic fibrosis.J Cyst Fibros. 2015 May;14(3):293-304. doi: 10.1016/j.jcf.2015.03.012. Epub 2015 Apr 14. J Cyst Fibros. 2015. PMID: 25881770 Review.
Cited by
-
Growth and laboratory maintenance of Pseudomonas aeruginosa.Curr Protoc Microbiol. 2012 May;Chapter 6:Unit 6E.1.. doi: 10.1002/9780471729259.mc06e01s25. Curr Protoc Microbiol. 2012. PMID: 22549165 Free PMC article.
-
Synthesis and Antimicrobial Activity of Phosphonopeptide Derivatives Incorporating Single and Dual Inhibitors.Molecules. 2020 Mar 28;25(7):1557. doi: 10.3390/molecules25071557. Molecules. 2020. PMID: 32231126 Free PMC article.
-
Ralstonia infection in cystic fibrosis.Epidemiol Infect. 2017 Oct;145(13):2864-2872. doi: 10.1017/S0950268817001728. Epub 2017 Aug 9. Epidemiol Infect. 2017. PMID: 28791938 Free PMC article.
-
Prospective evaluation of nontuberculous mycobacteria disease in cystic fibrosis: The design of the PREDICT study.J Cyst Fibros. 2024 Jan;23(1):50-57. doi: 10.1016/j.jcf.2023.08.007. Epub 2023 Sep 4. J Cyst Fibros. 2024. PMID: 37666709 Free PMC article.
-
Evaluation of colistin susceptibility in multidrug-resistant clinical isolates from cystic fibrosis, France.Eur J Clin Microbiol Infect Dis. 2013 Nov;32(11):1461-4. doi: 10.1007/s10096-013-1898-5. Epub 2013 May 30. Eur J Clin Microbiol Infect Dis. 2013. PMID: 23719852
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical